A source confirmed today that Amedica has definitely dropped its pursuit in acquiring U.S. Spine as a result of too much baggage, in terms of debt. The asking price was probably totally unrealistic. I guess this opens up the potential for another early-growth stage company to enter the "I want to be acquired" race. TSB envisions a company that generates an estimated $8-$10 million in revenue, being offered 1.5X for their company. $12 - $15 million dollars sounds right. You know what Steve Miller sang, "take the money and run." TSB wonders whom our readers think would be a viable acquisition? If I were Amedica I would continue to focus on the recon market with their self=proclaimed super duper material, and sell off whatever they have in their spine portfolio.
Seems like there are some companies that are hanging on a shoes string. Applied Spine may be in some trouble along with anyone else looking to bring a dynamic stabilization system to the market. What ever happened to Eden Spine? Are they generating any revenue? Lastly, TSB finds it interesting that Stem Cells seem to be the topic du jour, most days on the OTW website, You know what they say about those financial people, they sure know how to be market makers, even if there is more fiction than truth. Is NuVasive heading for another bout with the insurance industry regarding XLIF? TSB's been watching that stock, and maybe there is some truth to the scuttlebutt on the Street.
As we approach the Labor Day Weekend, remember to fire up the Barbie, crack open a cold one and sing in unison, make the world go away. TSB wants to know what our readers think?